Ohad Benjamini

Fixed-Duration Ibrutinib-Venetoclax in Patients with Chronic Lymphocytic Leukemia and Comorbidities

Arnon P. Kater, Carolyn Owen, Carol Moreno et al. · NEJM Evidence · 2022 · 208 citations

Immunology, Pathology, Fixed-duration Ibrutinib-venetoclax +16

Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes

Ohad Benjamini, Preetesh Jain, Long Trinh et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2014 · 149 citations · Full text

Hematological Malignancy, Tumor Biology, Lymphoid Neoplasia +14

Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination

Yair Herishanu, Galia Rahav, Shai Levi et al. · Blood · 2021 · 121 citations · Full text

Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

Carsten Utoft Niemann, Talha Munir, Carol Moreno et al. · The Lancet Oncology · 2023 · 117 citations

Hematological Malignancy, Lymphoid Neoplasia, Chronic Lymphocytic Leukaemia +10

The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression

Michal Abraham, Shiri Klein, Baruch Bulvik et al. · Leukemia · 2017 · 106 citations

Medicine, Apoptosis, Immunology +8